CATTEC V – Sneek Peek at investment-ready companies that Presented Oct 11-12 | MRUN

CATTEC V – Sneek Peek at investment-ready companies that Presented Oct 11-12

Presenting companies at CATTEC V
Twelve emerging investment-ready companies associated with Midwest universities, accelerators, and seed incubators showcased their opportunities to investors from across the region at CATTEC V Oct 11-12.   Each presenting company had 5 minutes to provide a fast pitch on their opportunity.

The fast pitch presenters provided an overview of their organization with emphasis on how investors can best access information to follow up on opportunities. Selection was based on the quality of the investment opportunity with a focus on representation of companies across the Midwest.  Companies and their associated university or  accelerators brought materials for display at tables in the reception area throughout the two-day event.  The presenting companies are listed here in alphabetical order.

Advanced Cooling Therapy (ACT)

Eric Kulstad, CEO

Chicago, IL  A PROPEL Company


Advanced Cooling Therapy (ACT) is developing a patented, disposable medical device enabling cost-effective patient temperature control that saves lives.  ACT provides a revolutionary and innovative platform technology that enables easy implementation of therapeutic hypothermia, solving a significant, unmet customer need by providing clinicians with a safe, efficient, and easy-to-use method to control a patient’s temperature, and addressing a $1B market with >15% annual growth.  ACT’s device is less invasive than competitors’ methods and has strong market pull. To support a targeted launch in 2013, ACT is currently seeking $1.2M in convertible debt, with 1/3 soft-circled to date.


Biophotonics Solutions, Inc.

Marcos Dantus, Founding CEO

East Lansing, MI  a Michigan State University Technologies company


Biophotonic Solutions Inc. is an innovative laser-technology company with global sales of $1.5M annually.  Its products are integrated onto other firms’ laser systems, “turbo charging” them and incredibly boosting their performance.    BSI has exclusive license to disruptive technology that unleashes latent capabilities of ultra-fast “femto-second” lasers.  BSI’s vision is driving the transition of ultrafast lasers from research labs – a sizable opportunity itself – into high value, real-world applications.   To capitalize on its opportunities and grow sales to $52M by 2017, BSI plans two infusions of capital:  a $750K seed round in Q4/2012 and a $1M Series A in Q3/2013.


Cearna, Inc.

Jo Polich, CEO

Naperville, IL   A PROPEL company

Cearna provides a family of products designed to reduce bruising, swelling & pain in trauma and surgical procedures. The first product to market is a plastic surgery product and is 50X more potent than any other competitor in the market. It is designed to reduce recovery time by 5-7 days. The market in the US for Cearna products is $33 billion and the plastics market alone is $237 million. The company began selling its product in the US in September 2012. Cearna has 2 patents pending and we are seeking $700,000 in funding.


Cell Habitats

John Flavin, Interim CEO

Woodridge, IL  A PROPEL Company

Cell Habitats (“CH”) is redefining the field of tissue regeneration by using biophysical cues to harness the body’s’ own stem cells to restore normal function to damaged or diseased tissue. CH’s novel approach, which doesn’t involve delivery of stem cells, is accomplished by injecting biodegradeable, biomimetic, microstructural devices (“Regenerod(s)”) that attract endogenous stem cells and behave as a surrogate cellular habitat that promotes endogenous stem cell growth. This innovation could potentially improve outcomes in the treatment of heart muscle injury, and may serve as a platform for the regeneration of other tissues such as bone, cartilage, muscle, and nerve tissues.


Citrics Biomedical

A.J. Noronha, Co-founder, interim President, & Director of Business Development

Chicago, IL  a PROPEL Company


Our lead product, CitrOSponge, is an innovative nanocomposite solving large needs in the $3.5B orthopedic market. We have successfully completed prototyping & 1 year of in vivo testing, demonstrating improved healing time & bone formation. The FDA 510k pathway provides an efficient pathway to market, creating an excellent opportunity for company & investors to reach commercialization within 2-3 years for $2-3MM in funding.   We have worked with IBIO PROPEL (our endorser) for over three years,  were a finalist in their Business Plan Competition, and have also received recognition from numerous Midwestern universities, including University of Chicago, Northwestern, Purdue, & Notre Dame.



Jack Heinemann CEO

Madison, WI  a Hybrid Zone X company

Ebullient’s technology is based on using an environmentally friendly dielectric refrigerant through proprietary cooling modules mounted on the hot surfaces in the computer.  It incorporates an evaporation process that results in high density heat removal.    The  innovation is based on design of tooling modules and system integration: Cooling modules are based on two-phase impinging jets and surfaces enhanced to amplify the heat transfer, careful design of jets is necessary to obtain a uniform heat removal from computer chips, with a minimum pressure drop.  System integration of multiple modules is obtained by arranging the modules in series to cool multiple surfaces on same server.


FxRedux Solutions

Don Anderson,  CEO and Co-founder

Iowa City, IA   A University of Iowa Research Foundation company


FxRedux Solutions provides pre-operative planning services for articular fracture surgery. We utilize 3D puzzle-solving software and complementary technologies to help surgeons more precisely restore broken bones. A surgeon requests our services at the time that they request a standard CT scan. CT studies are sent to us over the internet for analysis, and we return a report to the surgeon well in advance of surgery. The U.S. market, based initially on only three types of fractures, is approximately $111 million. We have established proof-of-concept functionality, but there is a gap of approximately $500,000 standing between us and entering the market.


Memcine Pharmaceuticals

Kate Holt, CEO

Iowa City, IA   A University of Iowa Research Foundation company


Memcine Pharmaceuticals is developing ImmunoplexTM, a platform technology aimed at transforming the $26B global vaccine market.  ImmunoplexTM promises to deliver cost effective needle-free vaccines without side effects associated with traditional vaccines.  Proof of concept has been achieved.  Composition-based patent applications have been filed in collaboration the University of Iowa Research Foundation.  Memcine’s business strategy is to function as a discovery engine and out-license by field and territory.  Memcine is in active partnering discussions around influenza and ebola vaccines.  Memcine seeks early stage financing to complete ongoing preclinical studies and advance the lead influenza vaccine to IND filing by 1Q 2014.



Charles Stack, CEO

Chicago, IL   An Illinois Institute of Technology company at University Tech Park


Neochloris, Inc. has developed a patent-pending photobioreactor to efficiently capture carbon dioxide emissions from industrial sources and convert these to algae biomass.  Unlike competing ponds, our innovation enables algae production in any geographic location.  We reduce energy inputs, increase algae yields, minimize contamination and boost biofuel production, enhancing project economics.  Full-scale Neochloris algae systems will have an ROI of less than two years, producing algae biofuel for less than $2.00 per gallon.  A utility customer has offered us a coal-fired power plant as a test site, and we seek funding to build a large-scale pilot plant to demonstrate the technology.


Nerve Access, Inc.

Chicago, IL  A PROPEL Company

Yaser Maksoud


Nerve Access is developing a high-potential Alzheimer’s therapeutic (NA135) that is believed to be effective and easy to administer.  An effective Alzheimer’s therapeutic could create $5B/year in a market that can easily expand to $20B.  The FDA has placed NA135 on a quick path to approval requiring only short-term studies.  We are close to filing an IND and we need $3 to $4 million to place NA135 in Phase II of clinical trials which is a very attractive milestone for big pharma to get involved.  We filed for Utility and PCT patent protection in June of 2012.


ROS Technologies

Dr. Samuel Dudley, President and CEO

Chicago Il,  A PROPEL company

ROS Technologies is a small biotechnology company developing its first product ,PulsePredicTM.  PulsePredicTM is a blood test which discriminates with high predictive power who will and will not need an implanted defibrillator to prevent abnormal heartbeats and subsequent sudden death.  In the US, the market opportunity for a blood test to predict arrhythmic risk includes at least 550,000 people per year, 5,000 hospitals, and 20,000 cardiologists. The technology is protected by patents.  Pricing is anticipated to be $200/test.  ROS has received a $270,000 STTR NIH grant.  ROS is seeking $5 million in capital to conduct a validation trial suitable for FDA approval.



Joe Kremer, CEO

Madison, WI  a Hybrid Zone X company

Slipstream has developed an integrated web and mobile-based platform targeted at the recreation sports market.  Using technology Slipstream provides the nation’s 12,000 Parks and Recreation agencies a free web based application to manage their park, facilities, programs, volunteers and members. For recreation participants, families and volunteers, Slipstream, in partnership with the National Recreation and Parks Association, provides an easy way to search out programs, register, maintain personal statistics, review programs, and stay updated on schedules and locations through a web and mobile interface.  The Company will generate money through multiple revenue streams.  The company is seeking $250,000.


Zon Labs

Ken Dirkin, President

Lansing, MI   a Michigan State University Technologies company


MSU’s Confucius Institute developed Zon, an on-line role-playing game with a $1.5M grant.  Zon immerses users in a virtual Beijing, where every situation is a language learning encounter.  Early users are K-12 students, generating $100K+ yearly in license revenue.  The MSU team recently formed Zon Labs, LLC to reach $100M+ in revenue by 2017.  It will drastically expand education sales, targeting the 100K U.S. students studying Chinese.  Further, 100M+ “Serious Learners” globally pay $1,000 on average to learn Chinese.  Zon Labs seeks a seed round of $750K in Q4/2012.   Mid-term needs will be covered in a $1.5M+ infusion by Q3/2013.




More about CATTEC V

MCOIN logo

Access to significant investment opportunities can yield attractive returns but to realize that potential, ideas, talent and capital must come together.  CATTEC V continues this series of joint meetings of MRUN and the Midwest Co-Investment Network.  CATTEC V is October 11-12, 2012 at the Illinois Science and Tech Park in Skokie, IL.   As with earlier CATTECs this meeting, now expanded to two days,  brings together the key elements of commercial growth and innovation; people ideas and capital. The universities of the Midwest include some of the nation’s leading institutions with history of producing breakthrough technologies in information technology, life science, and energy technology. Complementing the technologies coming out of university labs, several new seed accelerators have sprung up in the region that nurture and craft fundable deals based on the technologies of tomorrow. CATTEC V will showcase emerging technologies and startups from MRUN participating universities and from leading accelerators from around the Midwest.

This will be MRUN’s  Fall meeting and it will focus on the investment landscape in the Midwest from angel, through VC and the limited partners that invest in venture capital.  Collectively this ‘food chain’ of capital makes investments that determine that ability of high tech ventures across the region to form and grow.  Our keynote speaker will be Steve Burrill, Chairman of Burrill and Company.  Mr. Burrill will lead off the program on Oct 12.  The luncheon keynote on Oct 11 will be Mr. Paul Cohn, Vice President and Regional Director, The Ohio Capital Fund.

Thanks to our Bronze Sponsors:

Edwards Wildman Palmer, LLP

Legal and business advisers —providing the strategic, collaborative and client-focused
counsel that helps protect and advance their business goals.

Edwards Wildman Palmer
State-of-the-art facilities designed to help propel a broad spectrum of technological and scientific innovation,

More than 800 attorneys in the U.S. and in London offering a national platform and an international gateway to serve changing client business and legal needs
Thanks to our Event host:

Illinois Science and Technology Park